Navigation Links
Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing From $360 Million in 2008 to $450 Million in 2018
Date:11/17/2009

WALTHAM, Mass., Nov. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of agents to treat acute ischemic stroke will remain relatively flat over the next decade, increasing from $360 million in 2008 to $450 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Acute Ischemic Stroke finds that broadening the use of the recombinant tissue plasminogen activator (rt-PA; Genentech's Activase, other brands) and innovative therapies like stroke devices, such as Concentric Medical's Merci Retrieval System, will be important near-term advancements in the treatment of this indication. According to the report, drug-treatment rates for acute ischemic stroke will fluctuate modestly as the use of thrombolysis gradually increases, aided by continued improvements in stroke care throughout the major pharmaceutical markets.

Activase is now recommended for intravenous administration within 4.5 hours of stroke onset , as a result of recent positive clinical trial results from the third European Cooperative Acute Stroke Study (ECASS III). The report finds that the slowly expanding use of Activase will contribute to a modestly growing market through 2018, but a variety of limiting factors will continue to constrain the adoption of this and other time-sensitive treatments, and the promise of emerging therapies for acute ischemic stroke remains highly uncertain.

"In light of the recent discontinuations of several clinical-stage products, the stroke market continues to be a graveyard for drug development," said Decision Resources Analyst Jonathan Searles, B.A. "While drug developers continue to investigate novel therapies to expand the stroke armamentarium, interviewed experts express their lingering doubts about the clinical potential of late-stage compounds such as Paion AG/Lundbeck's thrombolytic desmoteplase and D-Pharm's DP-b99, and they lament the historically high rate of attrition among stroke therapeutics."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                      Decision Resources, Inc.
    Christopher Comfort                     Elizabeth Marshall
    781-296-2597                            781-296-2563
    ccomfort@dresources.com                 emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  As people age, it ... multitude of recommended screenings and tests that are linked ... priority. However, for the majority of aging individuals, hearing ... planning. For the 37.5 million American adults who report ... present to make hearing health a 2016 healthy aging ...
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... Chairman and CEO, will be presenting at Source Capital Group,s ... York, NY at 2:15 p.m. ET on Wednesday, ... Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... approximately one hour after the conclusion of the live event. ...
Breaking Medicine Technology:
(Date:2/7/2016)... Michigan (PRWEB) , ... February 07, 2016 , ... Women's ... of National Wear Red Day. National Wear Red Day is the first Friday ... women. Heart disease and stroke cause 1 in 3 deaths among women each year ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: ... color grades to their footage. A LUT is a Lookup Table that contains a ... corresponding color indicated by the table. By manipulating each pixel, LUT's can change each ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... of the company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider ... Improvements in design and manufacturing not only reduce the weight of the unit, ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official ... NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in ... from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are ...
Breaking Medicine News(10 mins):